Please login to the form below

Not currently logged in
Email:
Password:

Lilly to run two Alzheimer's trials

Eli Lilly and Company is to begin enrolling patients in two trials investigating a potential treatment to delay the progression of Alzheimer's

Eli Lilly and Company is to begin enrolling patients in two phase III clinical trials investigating a potential treatment to delay the progression of mild to moderate Alzheimer's disease.

The identical, multi-centred, randomised, double-blind, placebo-controlled trials will enrol a total of 2,000 patients aged over 55, from over 16 countries. The trials, known as Expedition and Expedition 2, will examine solanezumab compared with a placebo over a treatment period of 18 months. Patients will be permitted to continue taking any treatments for the symptoms of the disease during their participation in the trials.

"Current therapies available to treat Alzheimer's disease may help with symptoms, but they haven't been proven to change the disease progression," said Dr Eric Siemers, medical director, Alzheimer's disease research for Eli Lilly and Company. "Biomarker results from a phase II solanezumab trial give us hope that Lilly is on a path towards a treatment that may slow the rate of progression of Alzheimer's disease."

The Expedition trial will be conducted in Argentina, Brazil, Canada, Japan, and United States. Expedition 2 will be conducted in Australia, France, Germany, Italy, Japan, Korea, Poland, Russia, Spain, Sweden, Taiwan, United Kingdom, and United States.

21st May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics